程序性死亡配体 1 (PD-L1) 表达对酪氨酸激酶抑制剂 (TKI) 对晚期 ROS1 重排非小细胞肺癌 (NSCLC) 患者疗效的预测价值仍有待探索。本研究分析了接受一线克唑替尼治疗的携带ROS1重排的晚期NSCLC患者，以评估基线PD-L1表达与克唑替尼疗效之间的相关性。 本研究收集了上海胸科医院371例诊断为ROS1重排的NSCLC患者的临床数据2017年11月至2022年12月期间的情况进行了审查。根据基线PD-L1表达将患者分为三组：肿瘤比例评分（TPS）<1%、TPS 1%-49%和TPS≥50%。测量一线克唑替尼治疗后的客观缓解率（ORR）、疾病控制率（DCR）和无进展生存期（PFS）。分析共纳入64例患者，其中16例患者处于TPS< 1% 组、TPS 1%-49% 组 22 人、TPS≥50% 组 26 人。总体 DCR 为 100%，总体 ORR 为 76.5%。 TPS<1% 组的 ORR 为 81.2% (13/16)，TPS 1%-49% 组为 63.6% (14/22)，TPS≥50% 组为 84.6% (22/26) （p = 0.218）。所有患者的中位 PFS 为 20.21 个月（95% CI：15.71-24.71），TPS<1% 组的中位 PFS 为 28.96 个月（95% CI：19.87-38.04），为 17.56 个月（95% CI： TPS 1%-49% 组为 12.25-22.86，TPS≥50% 组为 25.85 个月（95% CI：18.52-33.17）（p = 0.100）。 CD74 融合患者的中位 PFS 为 18.23 个月 (95% CI: 15.24-21.22)，而非 CD74 融合患者的 PFS 为 16.49 个月 (95% CI: 9.75-23.23) (p = 0.359)。研究发现，患有晚期 ROS1 重排 NSCLC 的患者可从一线克唑替尼治疗中获益，无论基线 PD-L1 表达如何。版权所有 © 2024 Elsevier B.V. 保留所有权利。

The predictive value of programmed death-ligand 1 (PD-L1) expression for the efficacy of tyrosine kinase inhibitors (TKIs) in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC) remains underexplored. This study analyzed patients with advanced NSCLC harboring ROS1 rearrangements who received first-line crizotinib to evaluate the correlation between baseline PD-L1 expression and crizotinib efficacy.In this study, the clinical data from 371 patients diagnosed with ROS1-rearranged NSCLC at Shanghai Chest Hospital between November 2017 and December 2022 were reviewed. The patients were categorized into three groups according to the baseline PD-L1 expression: tumor proportion score (TPS) <1%, TPS 1 %-49 %, and TPS≥50 %. The objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) following first-line crizotinib treatment were measured.A total of 64 patients were included in the analysis, with 16 patients in the TPS<1% group, 22 in the TPS 1 %-49 % group, and 26 in the TPS≥50 % group. The overall DCR was 100 %, and the overall ORR was 76.5 %. The ORRs were 81.2 % (13/16) in the TPS<1% group, 63.6 % (14/22) in the TPS 1 %-49 % group, and 84.6 % (22/26) in the TPS≥50 % group (p = 0.218). The median PFS across all patients was 20.21 months (95 % CI: 15.71-24.71), with a median PFS of 28.96 months (95 % CI: 19.87-38.04) in the TPS<1% group, 17.56 months (95 % CI: 12.25-22.86) in the TPS 1 %-49 % group, and 25.85 months (95 % CI: 18.52-33.17) in the TPS≥50 % group (p = 0.100). The median PFS for patients with CD74 fusion was 18.23 months (95 % CI: 15.24-21.22), while those with non-CD74 fusion exhibited a PFS of 16.49 months (95 % CI: 9.75-23.23) (p = 0.359).Patients with advanced ROS1-rearranged NSCLC were found to benefit from first-line crizotinib treatment, irrespective of baseline PD-L1 expression.Copyright © 2024 Elsevier B.V. All rights reserved.